Effet de la stimulation transcutanée du nerf vague auriculaire (taVNS) sur les taux plasmatiques d'insuline (TaVNS)
The vagus or vagal nerve is a nerve that sends signals from the brain to other parts of the body to control involuntary functionm, including stomach function, and it is important to the regulation of insulin, C-peptide, and glucose levels. The purpose of this study is to evaluate whether electrically stimulating the nerve around the external ear will also stimulate the internal vagus nerve and influence the levels of insulin, C-peptide, and glucose. If it does, investigators hope that this will help innovate treatment of patients with nausea, vomiting, and disordered stomach function, and patients with diabetes.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Healthy volunteer subjects will be recruited for this project, which will be completed at a up to 2 study visits.
Prior to each visit, participants will be asked not to eat or drink anything (except a small amount of water to take medications) for 8-10 hours.
When participants arrive to Study Visit 1, they will be asked to lie in a supine position and will be fitted with:
- ECG electrodes, placed on the chest, arms/legs for electrocardiogram (ECG) recordings and behind each ear and just below the jaw on each side to record vagal nerve activity
- a butterfly needle catether for blood sample collections.
After the ECG electrodes are placed and the butterfly needle catheter is inserted, the first of 4 blood samples will be collected. The TENS unit clip will then be placed (after cleaning the left ear with an alcohol wipe) and a 20 minute baseline recording will be made, followed by the collection of a second blood sample.
Participants will then undergo their randomly assigned experimental condition (either active stimulation delivered via the TENS device, or no stimulation) for 40 minutes. At the end of the experimental period, a third blood sample is collected and the TENS device is turned off (for participants in the active stimulation group). Participants will then continue to lie on their back for an additional 20 minutes of recovery, after which the fourth and final blood sample is collected. The TENS clip is then removed and the study visit is complete.
Continuous vagal nerve and ECG recordings are obtained during the baseline, experimental, and recovery periods.
Participants will be asked if they wish to return for a second study visit, at which no TENS clip will be placed but the remaining Visit 1 procedures will be repeated.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Maureen Schilling, BS
- Numéro de téléphone: 3172782064
- E-mail: maschi@iu.edu
Lieux d'étude
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Indiana University Hospital
-
Contact:
- Maureen Schilling, BS
- Numéro de téléphone: 3172782064
- E-mail: maschi@iu.edu
-
Contact:
- Thomas V Nowak, MD
- Numéro de téléphone: 3179484272
- E-mail: tvnowak@iu.edu
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy Volunteers
- Aged 18-70
- Willing to have ECG electrodes placed on their neck and chest areas.
- Willing to have electrodes placed in the external ear.
- Willing to have an indwelling catheter placed to avoid multiple sticks for blood draw.
Exclusion Criteria:
- Unable to provide consent.
- Diabetes diagnosis per patient report
- Having known allergies to adhesive on electrode pads or bandages
- Having gastric motility issues as determined by the PI or clinical coordinator.
- Taking any medications that may affect gastric motility or cardiac variability, i.e. alpha or beta blockers for hypertension.
- Pregnant females
- Those unwilling to have the taVNS device placed in their ear.
- Those unwilling to consent to a blood draw.
- Prisoners
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Active Stimulation, then No electrodes
After an initial baseline blood sample is drawn, a TENS unit electrode clip will be placed on the inside of the outer ear and vagal nerve recordings are initiated. After 20 minutes of baseline recording, a second blood sample is drawn, after which, the TENS unit is turned ON for 40 minutes of stimulation. At the end of the stimulation period, a third blood sample is drawn and the TENS device is then turned OFF. After 20 minutes of recovery, a fourth and final sample of blood is drawn. Vagal nerve activity recordings are continued until the final blood sample is drawn. Subjects will be asked to return for an additional visit during which the TENS unit will not be placed, but the same vagal nerve recordings and blood draws will be obtained. |
For participants in the active stimulation group, electrical stimuli are delivered continuously for 40 minutes at a pulse width of 300 microseconds, pulse frequency of 25 Hz, and pulse amplitude of 0.5 to 1.5 mA based on the tolerance of the patient. Stimuli current and frequency may be decreased, if necessary, to minimize participant discomfort. |
|
Comparateur factice: Sham Stimulation, then No Electrodes
After an initial baseline blood sample is drawn, a TENS unit electrode clip will be placed on the inside of the outer ear, but will not be turned on. Vagal nerve recordings will be initiated. After 20, 60 and 80 minutes, additional blood samples are drawn. Vagal nerve activity recordings are continued until the final blood sample is drawn. Subjects will be asked to return for an additional visit during which the TENS unit will not be placed, but the same vagal nerve recordings and blood draws will be obtained. |
The TENS device will be placed but not turned on. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in plasma insulin levels
Délai: Study Days 1 and 2
|
Repeated measures analysis of variance will be used to determine the effects of stimulation period (baseline, end of stimulation, end of non-stimulation) and active/control group on plasma insulin levels. |
Study Days 1 and 2
|
|
Change in C-peptide levels
Délai: Study Days 1 and 2
|
Repeated measures analysis of variance will be used to determine the effects of stimulation period (baseline, end of stimulation, end of non-stimulation) and active/control group on C-peptide levels. |
Study Days 1 and 2
|
|
Change in glucose levels
Délai: Study Days 1 and 2
|
Repeated measures analysis of variance will be used to determine the effects of stimulation period (baseline, end of stimulation, end of non-stimulation) and active/control group on glucose levels |
Study Days 1 and 2
|
|
Change in heart rate variability
Délai: Study Days 1 and 2
|
Repeated measures analysis of variance will be used to determine the effects of stimulation period (baseline, end of stimulation, end of non-stimulation) and active/control group on heart rate variability. |
Study Days 1 and 2
|
|
Association between changes in heart rate variability and plasma insulin levels
Délai: Study Days 1 and 2
|
Pearson's correlation coefficients will be used to evaluate the association between change in heart rate variability (end of stimulation minus baseline) with changes in plasma insulin levels (end of stimulation minus baseline). Heart rate variability will be used as an indication of changes in parasympathetic or sympathetic activation. |
Study Days 1 and 2
|
|
Association between changes in heart rate variability and C-peptide levels
Délai: Study Days 1 and 2
|
Pearson's correlation coefficients will be used to evaluate the association between change in heart rate variability (end of stimulation minus baseline) with changes in C-peptide levels (end of stimulation minus baseline). Heart rate variability will be used as an indication of changes in parasympathetic or sympathetic activation. |
Study Days 1 and 2
|
|
Association between changes in heart rate variability and glucose levels
Délai: Study Days 1 and 2
|
Pearson's correlation coefficients will be used to evaluate the association between change in heart rate variability (end of stimulation minus baseline) with changes in glucose levels (end of stimulation minus baseline). Heart rate variability will be used as an indication of changes in parasympathetic or sympathetic activation. |
Study Days 1 and 2
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Correlation between gender and changes in circulating plasma insulin levels
Délai: Study Days 1 and 2
|
Pearson's correlation coefficient will be calculated for the association between change in circulating plasma insulin levels (end of stimulation minus baseline) and patient gender. |
Study Days 1 and 2
|
|
Correlation between age and changes in circulating plasma insulin levels
Délai: Study Days 1 and 2
|
Pearson's correlation coefficient will be calculated for the association between change in circulating plasma insulin levels (end of stimulation minus baseline) and patient age. |
Study Days 1 and 2
|
|
Correlation between body mass index and changes in circulating plasma insulin levels
Délai: Study Days 1 and 2
|
Pearson's correlation coefficient will be calculated for the association between change in circulating plasma insulin levels (end of stimulation minus baseline) and patient body mass index. |
Study Days 1 and 2
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Chercheur principal: Thomas V Nowak, MD, IU Medical Scool
Publications et liens utiles
Publications générales
- Krasaelap A, Sood MR, Li BUK, Unteutsch R, Yan K, Nugent M, Simpson P, Kovacic K. Efficacy of Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol. 2020 Aug;18(9):1987-1994.e2. doi: 10.1016/j.cgh.2019.10.012. Epub 2019 Oct 14.
- van der Voort IR, Becker JC, Dietl KH, Konturek JW, Domschke W, Pohle T. Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. Exp Clin Endocrinol Diabetes. 2005 Jan;113(1):38-42. doi: 10.1055/s-2004-830525.
- Vosseler A, Zhao D, Fritsche L, Lehmann R, Kantartzis K, Small DM, Peter A, Haring HU, Birkenfeld AL, Fritsche A, Wagner R, Preissl H, Kullmann S, Heni M. No modulation of postprandial metabolism by transcutaneous auricular vagus nerve stimulation: a cross-over study in 15 healthy men. Sci Rep. 2020 Nov 24;10(1):20466. doi: 10.1038/s41598-020-77430-2.
- Kozorosky EM, Lee CH, Lee JG, Nunez Martinez V, Padayachee LE, Stauss HM. Transcutaneous auricular vagus nerve stimulation augments postprandial inhibition of ghrelin. Physiol Rep. 2022 Apr;10(8):e15253. doi: 10.14814/phy2.15253.
- Yin J, Ji F, Gharibani P, Chen JD. Vagal Nerve Stimulation for Glycemic Control in a Rodent Model of Type 2 Diabetes. Obes Surg. 2019 Sep;29(9):2869-2877. doi: 10.1007/s11695-019-03901-9.
- Payne SC, Ward G, Fallon JB, Hyakumura T, Prins JB, Andrikopoulos S, MacIsaac RJ, Villalobos J. Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model. Physiol Rep. 2022 Apr;10(8):e15257. doi: 10.14814/phy2.15257.
- Hampton RF, Jimenez-Gonzalez M, Stanley SA. Unravelling innervation of pancreatic islets. Diabetologia. 2022 Jul;65(7):1069-1084. doi: 10.1007/s00125-022-05691-9. Epub 2022 Mar 29.
- Zhu Y, Xu F, Lu D, Rong P, Cheng J, Li M, Gong Y, Sun C, Wei W, Lin L, Chen JDZ. Transcutaneous auricular vagal nerve stimulation improves functional dyspepsia by enhancing vagal efferent activity. Am J Physiol Gastrointest Liver Physiol. 2021 May 1;320(5):G700-G711. doi: 10.1152/ajpgi.00426.2020. Epub 2021 Feb 24.
- Huang F, Dong J, Kong J, Wang H, Meng H, Spaeth RB, Camhi S, Liao X, Li X, Zhai X, Li S, Zhu B, Rong P. Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study. BMC Complement Altern Med. 2014 Jun 26;14:203. doi: 10.1186/1472-6882-14-203.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 24300
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The blood samples collected will be processed in the CRC lab to obtain blood serum. This serum will then be transferred to Dr. Robert Considine at the Indiana University Center for Diabetes and Metabolic Diseases. These samples will only be identified with the study subject number and which blood draw number (1,2,3) the vial contains.
ECG recordings are digitized and downloaded to a computer and are analyzed using heart rate variability software (LABVIEW, AD Instruments, Boston, MA). This software contains no references to any person and only contains the subject number for the study.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .